research RASopathic alopecia: Hair changes associated with vemurafenib therapy
Vemurafenib therapy can cause hair loss, but clobetasol propionate foam can help regrow hair.
Search
for
Sort by
Research
780-810 / 1000+ results 
research GBP1 as a machine learning-prioritized biomarker and therapeutic target for epstein-barr virus-induced clear cell renal cell carcinoma: multi-omics causal validation
GBP1 is a key target for treating Epstein-Barr virus-related kidney cancer, and finasteride may help.
research Scanning electron microscopy of ibrutinib-induced hair shaft changes
research Treatment of severe alopecia areata with oral tofacitinib: A case series
Oral tofacitinib may be an effective and tolerable treatment for some people with severe alopecia areata.
research Canagliflozin alleviates progestin resistance by suppressing RARβ/CRABP2 signaling in THRB knockout endometrial cancer cells
Canagliflozin helps overcome progestin resistance in certain endometrial cancer cells.
research Unexpected Effect of Baricitinib Use: Observation of a Case of Hypertrichosis
Baricitinib can cause excessive hair growth.
research 49690 Long-term efficacy of baricitinib in alopecia areata: 3-year results from BRAVE-AA1 and BRAVE-AA2
Baricitinib maintains significant hair regrowth in severe alopecia areata over three years.
research Efficacy and safety of tofacitinib in pediatric patients with alopecia areata: A prospective cohort study
Tofacitinib improved hair regrowth and quality of life in children with alopecia areata, with mild side effects.
research Experience with oral tofacitinib in 8 adolescent patients with alopecia universalis
Tofacitinib caused significant hair regrowth in adolescents with alopecia universalis who didn't respond to other treatments.
research Evidence-Based Data on How Long to Treat to Achieve Treatment Response With Baricitinib in Severe Alopecia Areata
Baricitinib treatment for severe alopecia areata shows significant improvement by 52 weeks, especially in very severe cases.
research Chemotherapy for children with medulloblastoma
Chemotherapy may help with survival in children with medulloblastoma, but more research is needed.
research A local drug delivery system based on visible light-cured glycol chitosan and doxorubicin⋅hydrochloride for thyroid cancer treatment in vitro and in vivo
GC10/DOX hydrogel shows promise as an effective thyroid cancer treatment.
research The Efficacy and Safety of Anlotinib Plus Etoposide with Cisplatin/Carboplatin in the First-Line Treatment of Lung Cancer: A Phase II Clinical Study
The treatment combination is effective and generally safe for lung cancer.
research Cold Atmospheric Plasma for Breast Cancer
Cold Atmospheric Plasma shows promise in treating aggressive breast cancer by targeting cancer cells while sparing normal tissue.
research Long-Term Efficacy of Ritlecitinib up to Month 24 From the ALLEGRO Phase 2b/3 and Long-Term Phase 3 Clinical Studies in Alopecia Areata
Ritlecitinib is effective for long-term treatment of severe alopecia areata.
research Vandetanib
A man developed alopecia areata after starting cancer treatment with vandetanib.
research Biotin and Acetazolamide for Treatment of an Unusual Child With Autism Plus Lack of Nail and Hair Growth
Biotin and acetazolamide improved hair and nail growth, mental function, and reduced headaches in a child with autism.
research Cost‐Effectiveness Analysis of Ritlecitinib Compared With No Treatment in Patients With Severe Alopecia Areata in Japan
Ritlecitinib is cost-effective for severe alopecia areata in Japan.
research The coenzyme A precursor pantethine enhances antitumor immunity in sarcoma
Pantethine may boost the immune system's ability to fight sarcoma.
research Therapeutic implications of topical cetirizine 1% in treatment of male androgenetic alopecia: A case‐controlled study
Topical cetirizine 1% promotes hair growth in male androgenetic alopecia patients.
research Myricetin: A Significant Emphasis on Its Anticancer Potential via the Modulation of Inflammation and Signal Transduction Pathways
Myricetin shows promise as an anticancer agent by reducing inflammation and enhancing drug effectiveness.
research Proteomic Predictors of Baricitinib Response in Severe Alopecia Areata: CCL11 Flags a Refractory Phenotype
High CCL11 levels may indicate poor response to baricitinib in severe alopecia areata.
research Acute inflammatory demyelinating polyneuropathy associated with pegylated interferon α 2a therapy for chronic hepatitis C virus infection
Pegylated interferon-alpha 2a can cause a rare nerve disorder, but early treatment can lead to full recovery.
research How Long to Treat to Achieve Desired Treatment Outcomes with Baricitinib 4 mg in Severe Alopecia Areata: Evidence-based Approach
Baricitinib 4 mg should be used for at least 1 year to see significant hair regrowth in severe alopecia areata.
research 471 Senolytic Potential of Fisetin and ABT Compounds in Dermal Fibroblasts
research B/N-doped carbon nano-onions as nanocarriers for targeted breast cancer therapy
Boron/nitrogen-doped carbon nano-onions improve targeted breast cancer treatment by enhancing drug delivery and reducing side effects.
research Effectiveness of baricitinib in severe alopecia areata in real life: a retrospective study of 87 patients.
Baricitinib is effective and safe for treating severe alopecia areata.
research Responses to Tetanus and Meningococcal Vaccines in Patients with Alopecia Areata Treated with Ritlecitinib
research Zinc: A complementary factor in the treatment of chronic hepatitis C? (Review)
Zinc supplementation may help improve treatment outcomes for chronic hepatitis C.
research Intermittent Low-dose Ritlecitinib in Refractory Paediatric Alopecia Areata: A Case Report with Therapeutic Implications
Low-dose Ritlecitinib may help children with stubborn Alopecia Areata.